A CRO FOR PRECLINICAL SERVICES IN ONCOLOGY

Antineo

Antineo

OUR STRENGTHS

OUR VERSATILITY

The reactivity, adaptability and flexibility of a human-sized compagny.

OUR PERSONALIZED ADVICE

A Scientific Advisory Board of clinical experts to understand your needs and projects.

SECONDARY RESISTANCE MODELS

Secondary resistance models to standards of care established and characterized through RNAseq and immunophenotyping of the tumor microenvironment.

OUR COMPETITIVE PRICES

To provide our customers with excellent value for money compared to the competition.

Antineo

ABOUT US

Spin-off of the Team Anticancer Antibodies
Centre de Recherche en Cancérologie (CRCL)

Company

CRO created in May 2015, specialized in proof-of-concept studies in oncology

Team

Scientists and efficient team recognized for its expertise in onco-pharmacology at the international level

Location

BioParc Rockefeller
Bâtiment BIOSERRA 2
Lyon

Customers

French and international clients composed of pharmaceutical, biotechnology companies and academic institutions

Regulation

- CIR agreement 2020-2025
- Fully authorized animal house and personnel

Track-record

- 200+ studies
- 40 sponsors
- 6 ongoing partnerships

Antineo

OUR TEAM

Renaud Marin-Sidgwick
CEO

Marie Tautou, PhD
Study Director
Head of Business Development

Charles Dumontet, MD-PhD
CSO - Consultant

Aurélie Cadiou
PhD student

Jean-Philippe Druet
Executive Assistant

Doriane Mathé
Study Manager

Marine Fellmann
Study Manager

Pierre-Antoine Choffour
Study Manager

Flore Sarraute
Apprentice

Antineo

THERAPEUTIC AREAS

Oncology and immuno-oncology

Small molecules



Biological molecules

Antibodies, peptides

Cellular and gene therapies

Antineo

OUR SERVICES

Antineo's services

Optimize and accelerate the development of our customers' compounds

Provide advice, expertise and services



Antineo

IN VITRO SERVICES

Cytotoxicity assays

Determination of IC50 / EC50

Synergy / Antagonism assay

Colorimetric method

Luminescence method

MTT

MTS

Cell Titer-Glo®





Cell viability / Cell metabolic activity / Cytotoxicity / Cell proliferation



Continuous-monitoring studies

Realize a real-time analysis of a variety of cellular and immunological processes



Characterisation of samples



Quantitative PCR

Western Blotting

ELISA assays

Immunoprecipitation



Flow cytometry studies

Flow Cytometry - (FACS)

Qualitative and quantitative multiparametric analyses

BD FACS CANTO™	LSR FORTESSA™	CYTEK
Classical	Classical	Spectral
3 lasers : 8 markers* maximum	4 lasers : 18 markers* maximum	5 lasers : up to 29 markers*







Antineo

EX VIVO SERVICES

Immunology services

Isolate the cells of interest and characterise your target molecule by Flow Cytometry

Partnership

- **Analysis on fresh samples** : on blood products (blood bags) and by products (buffy coat)

- Most assays can be performed as **end point** and **continuous-monitoring** studies

T cell based assays

Myeloid Cells based assays

ADCC assays with fresh NK cells

ADCP assays with fresh myeloid cells

Development of immunotherapies

Highlight the target and decipher the mechanisms of action of therapeutic antibodies

- **Immunology ex vivo assays** (T cell activation by IFNγ measurements, CTL assays, Macrophage polarisation etc.)
- In vitro or ex vivo **ADCC, ADCP and CDC assays** (calcein release)
- Original methods for **in vivo assessment of ADCC and CDC activities**
- Titration / Internalization / By-stander effect (ADC) …
- Original in vitro and in vivo assays for **bispecific antibodies** (anti-CD3)
- A unique panel of tumour models presenting **secondary resistances to immunotherapies**



Antineo

IN VIVO SERVICES

Animal facilities

- **High standards facility** with strictly **controlled environment**
- **Multiple types of experiments** : study cancer progression, assess the effectiveness and innocuity of novel therapies,...
- **Wide range of animal models** from **immune-competent** (C57Bl/6, CD1...) to **immune-deficient** (SCID-CB17, NSG, NOG, NOD-SCID...) and **humanized models** (BRGSF-HIS, huNOG-EXL)
- Capacity **over 3,000 mice**
- **Ethical compliance** and **expertise in animal experimentation**

Choice of tumor models

- 100+ cell-derived xenograft models
- 40 murine syngeneic models for immuno-oncology
- Subcutaneous or orthotopic implantation

01

Standard of care therapies

- As reference for the tested compound
- For comparison studies
- For combinaison / synergy studies

02

Protocol adapted to our clients' compounds

- Route (IV / IP / PO / IT)
- Galenic formulations (liposome encapsulation)
- Schedule of injection
- Schedule and duration of follow-up
- Weekly updates
- Choice of end-point (with control or individual ethical end-points)

03

In vivo analysis

Demonstrate the antitumor activity of a novel agent in animal models, as well as defining the dosage and schedule that is both efficient and non-toxic

- Recommendations on the choice of the best indication and model
- Systemic and haematological toxicity of your compounds in rodents (VetScan / MS9)
- Pharmacokinetics properties in mouse and rat
- Antitumor efficacy in human or mice tumour models
- Combination / comparison with gold standards

- Orthotopic models*
- Immunophenotyping of the tumour micro environment
- An original offer of secondary resistances to reference therapies (CDX and syngeneic)
- The development of models of resistance

**In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies*

ORIGINAL RESISTANT TUMOR MODELS

Acquired resistance to anti-PD(L)1



Our established resistance models



In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies

CDX Models

Lymphoma

Follicular Lymphoma - (RL model) *:*
- *Rituximab / GA101 / R-CHOP / R-DHAP)*

Mantle Cells Lymphoma - (Granta model) :
- *Rituximab*

Diffuse large B cells lymphoma - (Toledo model) :
- *Rituximab*

Burkitt's lymphoma
- Raji model : *Rituximab*
- Daudi model : *CAL-101*

Myeloma

Plasma cells myeloma model — RPMI8226
- *Daratumumab*

Multiple myeloma MM.1S
- *Daratumumab*

Breast

Tubular Adenocarcinoma BT474
- *T-DM1*

MDA-MB-361 model
- *Trastuzumab T-DM1*

Colorectal / Gastric

Gastric carcinoma NCI-N87
- *Trastuzumab*



Bespoke services : *On demand development of resistant models (Syngeneic or CDX models)*

Syngeneic Models

Colon

MC38 model
- *anti-PD1 / anti-PDL-1*

Bladder

MBT-2 model
- *anti-PD1*

MB49 model
- *anti-PD1 / anti-PDL-1*

Kidney

RENCA model
- *anti-PD1 / anti-PDL-1*

Melanoma

B-raf
- *anti-PD1 / anti-PDL-1*

N-Ras
- *anti-PD1 / anti-PDL-1*

Tyr N-Ras models
- *anti-PD1 / anti-PDL-1*

BRAND NEW : Pancreas

Kic8 model
- *PD1 / PDL1 / Gemcitabine*

Lymphoma

P388 model
- *anti-PD1 / anti-PDL-1*

CDX Models

Lymphoma

Follicular Lymphoma - (RL model) :
- *Rituximab / GA101 / R-CHOP / R-DHAP)*

Mantle Cells Lymphoma - (Granta model) :
- *Rituximab*

Diffuse large B cells lymphoma - (Toledo model) :
- *Rituximab*

Burkitt's lymphoma
- Raji model : *Rituximab*
- Daudi model : *CAL-101*

Myeloma

Plasma cells myeloma model — RPMI8226
- *Daratumumab*

Multiple myeloma MM.1S
- *Daratumumab*

Breast

Tubular Adenocarcinoma BT474
- *T-DM1*

MDA-MB-361 model
- *Trastuzumab T-DM1*

Colorectal / Gastric

Gastric carcinoma NCI-N87
- *Trastuzumab*

Bespoke services : *On demand development of resistant models (Syngeneic or CDX models)*



Syngeneic Models

Colon

MC38 model
- *anti-PD1 / anti-PDL-1*

Bladder

MBT-2 model
- *anti-PD1*

MB49 model
- *anti-PD1 / anti-PDL-1*

Kidney

RENCA model
- *anti-PD1 / anti-PDL-1*

Melanoma

B-raf
- *anti-PD1 / anti-PDL-1*

N-Ras
- *anti-PD1 / anti-PDL-1*

Tyr N-Ras models
- *anti-PD1 / anti-PDL-1*

BRAND NEW : Pancreas

Kic8 model
- *PD1 / PDL1 / Gemcitabine*

Lymphoma

P388 model
- *anti-PD1 / anti-PDL-1*

Partner platforms

CIQLE

Microscopy platform for Immunohistochemistry **(IHC)**

PROFIL EXPERT

High throughput sequencing, microdissection and single cell technologies

HAWKCELL

Platform for Magnetic Resonance Imaging (MRI)

IMTHERNAT

PET-Scan (Radiolabelling)

ANAQUANT

Detection and quantification of proteins by mass spectrometry

PAREAN BIOTECHNOLOGIES

Immune omics analysis (Single cell)

Antineo

OUR NEWS

IVIS® Lumina Series III Imager

MDA-MB-231 cell line



2023-04-05



2023-04-12



2023-04-26



- **In vivo and 2D imaging** of the tumors/metastasis
- **Precise tumor monitoring and follow-up**
- **Animal saving**
- **Biodistribution and efficacy studies**

Hepatic metastases of an MDA-MB-231 Luciferase (+) model by intrasplenic implantation

3D Bioprinting - *Ongoing development*

BT 474-GFP cell line



- **Recapitulate the tumor microenvironment** - (TME)
- **High-throughput screening**
- **Minimising animals used and costs**

Antineo

CASE STUDIES

Efficacy study





KIC8 Gemcitabine-resistant tumor growth



Toxicity study – Haematological analysis









mAb Titration assay (SK-BR3)



mAb Internalization assay (SK-BR3)




Antineo
THEY
TRUST US!


EVEXTA BIO


SAYENS
SATT
CATALYSEUR D'INNOVATIONS


yomi
PHARMA


mablink


advanced
biodesign


StromaCare


Roche


Breach Bio


CASINVENT


GAMAMABS
PHARMA


Jalon
THERAPEUTICS


PULSALYS


CRCL
CENTRE DE
RECHERCHE EN
CANCÉROLOGIE
DE LYON


Antineo

THANK YOU!

(+33) 4 72 36 15 71

www.antineo.fr

ANTINEO
2e étage - Bâtiment BIOSERRA 2
60F avenue Rockefeller
69008 LYON

Antineo